STOCK TITAN

NeuroSense Therapeutics Ltd - NRSN STOCK NEWS

Welcome to our dedicated news page for NeuroSense Therapeutics (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on NeuroSense Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroSense Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroSense Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
-
-
Rhea-AI Summary
NeuroSense Therapeutics has completed enrollment in the PARADIGM clinical trial for its drug PrimeC in amyotrophic lateral sclerosis (ALS) patients. The trial is a Phase 2b study that included 69 participants from Israel, Italy, and Canada. PrimeC is a combination therapy of celecoxib and ciprofloxacin that targets key ALS mechanisms. The primary efficacy endpoint of the trial is the assessment of ALS biomarkers, and the topline results are expected in Q4 2023. 96% of participants who completed the trial opted for treatment with PrimeC in the 12-month open label extension phase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
NeuroSense Therapeutics announces positive results from a biomarker study for the treatment of Parkinson's disease (PD). The study showed a significant decrease in AGO2 levels in newly diagnosed PD patients compared to healthy individuals. NeuroSense's combination platform therapy has shown potential in increasing AGO2 levels in ALS patients, indicating therapeutic potential in PD. NeuroSense is exploring co-development of a PD asset with potential collaborators.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
conferences
NeuroSense Therapeutics Ltd

Nasdaq:NRSN

NRSN Rankings

NRSN Stock Data

24.96M
10.65M
28.05%
0.91%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Herzliya

About NRSN

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa